Reductions in the striatal uptake of those radiophar-maceuticalsprovide a helpful marker of functional DAT loss, which is a valuable means ofsupporting or rejecting a diagnosis of parkinsonism associated with striataldopamine deficiency. This evidence concerns the gene SLC6A3 and Parkinson disease.